Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 691 to 698 of 698 results for must

  1. Introducing a new way of prioritising our guidance topics

    NICE's deputy chief executive, Jonathan Benger, talks about our new approach to prioritisation.

  2. How NICE is ensuring its topic prioritisation decisions are grounded in lived experience

    Simon Denegri discusses NICE’s commitment to involving the public voice in its work and decisions.

  3. NICE collaboration on streamlined licensing and patient access process for new medicines

    Companies can now submit medicines for the new Innovative Licensing and Access Pathway (ILAP) following close collaboration between the NICE, drug regulators, the NHS and equivalent organisations in Scotland.

  4. How NICE manages the potential conflicts of interests of patient experts

    People with lived experience provide valuable insight into the impact of NICE’s’ guidance and advice.

  5. Women inspiring inclusion in NICE guidance

    This International Women’s Day, we’re focusing on the invaluable contributions of 2 of the women who help shape our guidance through their independent voluntary committee roles. They talk to us about their involvement with NICE and what #InspireInclusion means to them.

  6. Patient safety and surgical innovation – why new isn't always better

    Jane Blazeby, Professor of Surgery, University of Bristol, University Hospitals Bristol and Weston and the NIHR Bristol Biomedical Research Centre, talks about the research she’s led to explore and address optimism bias and other issues in surgical innovation.

  7. Putting user needs at the heart of an advisory service for AI and data-driven technologies

    Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.

  8. NICE collaborates with international partner agencies to streamline the confidential marking process

    NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.